Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral CUDC-427, an Antagonist of Inhibitors of Apoptosis (IAP) Proteins, When Administered Twice Daily in Subjects With Advanced and Refractory Solid Tumors or Lymphoma

Trial Profile

A Phase I Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral CUDC-427, an Antagonist of Inhibitors of Apoptosis (IAP) Proteins, When Administered Twice Daily in Subjects With Advanced and Refractory Solid Tumors or Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CUDC 427 (Primary)
  • Indications Diffuse large B cell lymphoma; Lymphoma; Marginal zone B-cell lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Curis; Genentech
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Apr 2016 Status changed from recruiting to completed, as per results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 13 Apr 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top